牛牛AI助手已提取核心信息
Merck & Co. Inc. officer Robert M. Davis is set to sell 85,021 shares of the company's common stock on February 14, 2024, according to a recent filing. The shares, valued at an aggregate market value of $10,661,573.89, were acquired on the same date through the exercise of options under a registered plan. The transaction involves the payment of cash to the issuer for the securities. This sale follows a previous transaction in the past three months where Davis sold 150,000 shares for a total gross proceed of $18,872,130.
Merck & Co. Inc. officer Robert M. Davis is set to sell 85,021 shares of the company's common stock on February 14, 2024, according to a recent filing. The shares, valued at an aggregate market value of $10,661,573.89, were acquired on the same date through the exercise of options under a registered plan. The transaction involves the payment of cash to the issuer for the securities. This sale follows a previous transaction in the past three months where Davis sold 150,000 shares for a total gross proceed of $18,872,130.
默沙东公司根据最近的一份文件，公司高管罗伯特·戴维斯定于2024年2月14日出售该公司85,021股普通股。这些股票的总市值为10,661,573.89美元，于同日通过行使注册计划下的期权收购。该交易涉及向发行人支付证券的现金。此次出售是在过去三个月的上一笔交易之后进行的，当时戴维斯出售了15万股股票，总收益为18,872,130美元。
默沙东公司根据最近的一份文件，公司高管罗伯特·戴维斯定于2024年2月14日出售该公司85,021股普通股。这些股票的总市值为10,661,573.89美元，于同日通过行使注册计划下的期权收购。该交易涉及向发行人支付证券的现金。此次出售是在过去三个月的上一笔交易之后进行的，当时戴维斯出售了15万股股票，总收益为18,872,130美元。
有用
没用